BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 30069764)

  • 1. Vismodegib.
    Meiss F; Andrlová H; Zeiser R
    Recent Results Cancer Res; 2018; 211():125-139. PubMed ID: 30069764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vismodegib.
    Meiss F; Zeiser R
    Recent Results Cancer Res; 2014; 201():405-17. PubMed ID: 24756807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and preclinical development of vismodegib.
    Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
    Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hedgehog signaling pathway and cancer therapeutics: progress to date.
    Ruch JM; Kim EJ
    Drugs; 2013 May; 73(7):613-23. PubMed ID: 23605693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
    Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
    Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
    Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma.
    Dubey AK; Dubey S; Handu SS; Qazi MA
    J Postgrad Med; 2013; 59(1):48-50. PubMed ID: 23525058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.
    De Smaele E; Ferretti E; Gulino A
    Curr Opin Investig Drugs; 2010 Jun; 11(6):707-18. PubMed ID: 20496266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.
    Ruiz Salas V; Alegre M; Garcés JR; Puig L
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):741-9. PubMed ID: 24611655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hedgehog inhibitors: a patent review (2013 - present).
    Xin M
    Expert Opin Ther Pat; 2015 May; 25(5):549-65. PubMed ID: 25726713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.
    Lyons TG; O'Kane GM; Kelly CM
    Expert Opin Drug Saf; 2014 Aug; 13(8):1125-32. PubMed ID: 25033383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vismodegib for Basal Cell Carcinoma and Beyond: What Dermatologists Need to Know.
    Alkeraye SS; Alhammad GA; Binkhonain FK
    Cutis; 2022 Sep; 110(3):155-158. PubMed ID: 36446122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a potent hedgehog pathway inhibitor capable of activating caspase8-dependent apoptosis.
    Chen Q; Zhang H; Wu M; Wang Q; Luo L; Ma H; Zhang X; He S
    J Pharmacol Sci; 2018 Jul; 137(3):256-264. PubMed ID: 30064819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vismodegib: A Review in Advanced Basal Cell Carcinoma.
    Frampton JE; Basset-Séguin N
    Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vismodegib: a review.
    Ruiz-Salas V; Alegre M; López-Ferrer A; Garcés JR
    Actas Dermosifiliogr; 2014 Oct; 105(8):744-51. PubMed ID: 24359667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.